

# 2025 Current Fiscal Year Report: Gastrointestinal Drugs Advisory Committee

Report Run Date: 04/25/2026 12:37:49 AM

## 1. Department or Agency

Department of Health and Human Services

## 2. Fiscal Year

2025

## 3. Committee or Subcommittee

Gastrointestinal Drugs Advisory Committee

## 3b. GSA Committee No.

874

## 4. Is this New During Fiscal Year? 5. Current Charter 6. Expected Renewal Date 7. Expected Term Date

No 03/03/2024 03/03/2026

## 8a. Was Terminated During Fiscal Year?

No

## 8b. Specific Termination Authority

## 8c. Actual Term Date

## 9. Agency Recommendation for Next Fiscal Year

Continue

## 10a. Legislation Req to Terminate?

Not Applicable

## 10b. Legislation Pending?

Not Applicable

## 11. Establishment Authority Authorized by Law

## 12. Specific Establishment Authority

21 U.S.C. 394

## 13. Effective Date

11/28/1990

## 14. Committee Type

Continuing

## 14c. Presidential?

No

## 15. Description of Committee

Scientific Technical Program Advisory Board

## 16a. Total Number of Reports

No Reports for this Fiscal Year

## 17a. Open 0 17b. Closed 0 17c. Partially Closed 0 Other Activities 0 17d. Total 0

## Meetings and Dates

No Meetings

	<b>Current FY</b>	<b>Next FY</b>
<b>18a(1). Personnel Pmts to Non-Federal Members</b>	\$0.00	\$16,224.00
<b>18a(2). Personnel Pmts to Federal Members</b>	\$0.00	\$2,496.00
<b>18a(3). Personnel Pmts to Federal Staff</b>	\$49,890.00	\$50,372.00
<b>18a(4). Personnel Pmts to Non-Member Consultants</b>	\$0.00	\$0.00
<b>18b(1). Travel and Per Diem to Non-Federal Members</b>	\$0.00	\$30,749.00
<b>18b(2). Travel and Per Diem to Federal Members</b>	\$0.00	\$4,731.00
<b>18b(3). Travel and Per Diem to Federal Staff</b>	\$0.00	\$0.00
<b>18b(4). Travel and Per Diem to Non-member Consultants</b>	\$0.00	\$0.00
<b>18c. Administrative Costs (FRNs, contractor support, In-person/hybrid/virtual meetings)</b>	\$0.00	\$0.00
<b>18d. Other (all other funds not captured by any other cost category)</b>	\$12,473.00	\$32,365.00
<b>18e. Total Costs</b>	\$62,363.00	\$136,937.00
<b>19. Federal Staff Support Years (FTE)</b>	0.25	0.25

**20a. How does the Committee accomplish its purpose?**

The Committee reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of gastrointestinal diseases and makes appropriate recommendations to the Commissioner of Food and Drugs.

**20b. How does the Committee balance its membership?**

Members are authorities in the fields of gastroenterology, endocrinology, surgery, clinical pharmacology, physiology, pathology, liver function, motility, esophagitis, and statistics. The committee includes one technically qualified voting member who is identified with consumer interests. The Committee may include one non-voting member who is identified with industry interests.

**20c. How frequent and relevant are the Committee Meetings?**

The Committee did not meet during FY-25. It is expected that the Committee will meet 2-3 times during FY-26.

**20d. Why can't the advice or information this committee provides be obtained elsewhere?**

Members of the Committee are drawn from academia, research and/or clinical practice. They provide advice and input that FDA considers as part of its regulatory decision-making process. The alternate means of obtaining this advice would involve the recruitment of large numbers of scientist on a full-time basis at a maximum rate of compensation.

**20e. Why is it necessary to close and/or partially closed committee meetings?**

The Committee held no closed meetings during

FY-25.

## 21. Remarks

There were no reports required for this Committee in FY-25. Although this Committee did not meet in FY-25, considerable time was devoted to appointing members, maintaining associated records for these activities, and streamlining paper processes within FDA. In addition, time was spent in the routine care and maintenance of the Committee: the development of a financial report for this website; updating the roster and number of vacancies on our website; completing the annual ethics report; reviewing financial disclosures of current members and providing ethics training. Since the Committee did not meet, no reporting was required. Although the current charter states that the Committee shall hold meetings approximately 2-3 times a year, this is only an estimation based on data from previous years. As the FDA convenes advisory committees based on the needs of the Agency, it should not be construed as an exact figure. The committee chair is currently vacant on this committee.

## Designated Federal Officer

Jessica Seo Designated Federal Officer

Committee Members	Start	End	Occupation	Member Designation
Assis, David	04/23/2022	06/30/2025	Yale School of Medicine, Department of Internal Medicine, Section of Digestive Diseases	Special Government Employee (SGE) Member
Chang, Lin	09/16/2021	06/30/2025	Vice-Chief, Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at UCLA	Special Government Employee (SGE) Member

Coffey, Christopher	06/27/2024	06/30/2026	Professor and Director, Clinical Trials Statistical and Data Management Center, Department of Biostatistics, University of Iowa	Special Government Employee (SGE) Member
Crandall, Wallace	02/28/2024	10/31/2027	Associate Vice President – Medical, Immunology GI Therapeutic Area Head Eli Lilly and Company	Representative Member
Heller, Theo	09/09/2024	06/30/2028	Chief, Translational Hepatology Section, Senior Investigator, Liver Diseases Branch National Institute of Diabetes and Digestive Kidney Diseases, National Institutes of Health	Regular Government Employee (RGE) Member
Lebwohl, Benjamin	07/01/2017	06/30/2025	Professor of Medicine and Epidemiology; Director of Clinical Research, Celiac Disease Center, Columbia University College of Physicians & Surgeons	Special Government Employee (SGE) Member
Lee, Brian	09/09/2024	06/30/2028	Associate Professor of Medicine Division of Gastrointestinal and Liver Diseases, Keck School of Medicine University of Southern California	Special Government Employee (SGE) Member
McVey, Joy	03/19/2018	06/30/2025	CONSUMER REPRESENTATIVE - Program Manager, Volunteer Services, Emory Healthcare; Principal Consultant, Simply Joy, LLC	Special Government Employee (SGE) Member

**Number of Committee Members Listed: 8**

**Narrative Description**

FDA’s strategic priorities in responding to the public health

challenges of the 21st century are to advance regulatory science and innovation; strengthen the safety and integrity of the global supply chain; strengthen compliance and enforcement activities to support public health; expand efforts to meet the needs of special populations; advance medical countermeasures and emergency preparedness; advance food safety and nutrition; promote public health by advancing the safety and effectiveness of medical products; establish an effective tobacco regulation, prevention, and control program; and manage for organizational excellence and accountability. The Gastrointestinal Drugs Advisory Committee supports FDA's strategic priorities by reviewing and evaluating available data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of gastrointestinal diseases and makes appropriate recommendations to the Commissioner of Food and Drugs. This supports the development of safe and effective new medical technologies, and advances the status of the Agency as a science-based and science-led regulatory agency, providing global leadership in the protection of public health.

**What are the most significant program outcomes associated with this committee?**

Checked if  
Applies

- Improvements to health or safety
- Trust in government
- Major policy changes
- Advance in scientific research
- Effective grant making
- Improved service delivery
- Increased customer satisfaction
- Implementation of laws or regulatory requirements
- Other

**Outcome Comments**

NA

**What are the cost savings associated with this committee?**

Checked if Applies

- |                            |                                     |
|----------------------------|-------------------------------------|
| None                       | <input type="checkbox"/>            |
| Unable to Determine        | <input checked="" type="checkbox"/> |
| Under \$100,000            | <input type="checkbox"/>            |
| \$100,000 - \$500,000      | <input type="checkbox"/>            |
| \$500,001 - \$1,000,000    | <input type="checkbox"/>            |
| \$1,000,001 - \$5,000,000  | <input type="checkbox"/>            |
| \$5,000,001 - \$10,000,000 | <input type="checkbox"/>            |
| Over \$10,000,000          | <input type="checkbox"/>            |
| Cost Savings Other         | <input type="checkbox"/>            |

### **Cost Savings Comments**

The utilization of the Gastrointestinal Drugs Advisory committee enables the Agency to obtain required and frequently scarce professional services from medical and scientific experts not otherwise available to the Agency; and to obtain the services of these experts only on an as needed basis rather than on a full time basis. The service of the Committee resulted in advice for the improvement of public health, for which it is difficult to assign a financial value.

### **What is the approximate Number of recommendations produced by this committee for the life of the committee?**

26

### **Number of Recommendations Comments**

The Committee made 26 recommendations from FY-03 through FY-25.

### **What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?**

84%

### **% of Recommendations Fully Implemented Comments**

The function of an advisory committee is purely advisory in nature. Although the FDA most often accepts the recommendations from its committees, the advice is purely advisory in nature, therefore, the Agency has the option of not implementing the advice. This number represents an approximation of the percentage of recommendations that the agency has fully implemented or plans to fully implement.

### **What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?**

10%

**% of Recommendations Partially Implemented Comments**

The function of an advisory committee is purely advisory in nature. Although the FDA most often accepts the recommendations from its committees, the advice is purely advisory in nature, and therefore, the Agency has the option of not implementing the advice.

**Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?**

Yes  No  Not Applicable

**Agency Feedback Comments**

When appropriate, information is made available to the public. Actions related to guidance documents or other general matters issues are available publicly when implemented.

**What other actions has the agency taken as a result of the committee's advice or recommendation?**

Checked if Applies

- Reorganized Priorities
- Reallocated resources
- Issued new regulation
- Proposed legislation
- Approved grants or other payments
- Other

**Action Comments**

FDA approves or chooses not to approve new medical product.

**Is the Committee engaged in the review of applications for grants?**

No

**Grant Review Comments**

NA

**How is access provided to the information for the Committee's documentation?**

Checked if Applies

- Contact DFO
- Online Agency Web Site

Online Committee Web Site



Online GSA FACA Web Site



Publications



Other



**Access Comments**

NA